AbbVie submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) an...

Enhertu followed by THP supplemental biologics license application accepted in the U.S. for patients with...

Henlius receives the NMPA IND approval for Its PD-L1 targeting ADC HLX43 in combination with...

Enhertu demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1...

Starpharma announces a research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy...

Debiopharm licenses SunRock Biopharma’s anti-HER3/HER2 antibody to explore the full potential of bispecific ADC Debio...